- Home
- BGNE
BGNE
BeiGene Ltd.
as 07-26-2024 4:00pm EST
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
Upcoming Earnings Alert:
Get ready for potential market movements as BeiGene Ltd. BGNE prepares to release earnings report on 31 Jul 2024.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | GRAND CAYMAN |
| Market Cap: | 16.4B | IPO Year: | 2016 |
| Target Price: | $254.85 | AVG Volume (30 days): | 264.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $126.97 - $225.23 | Next Earning Date: | 07-31-2024 |
| Revenue: | $2,762,630,000 | Revenue Growth: | 77.42% |
| Revenue Growth (this year): | 829.85% | Revenue Growth (next year): | 29.14% |
Latest BeiGene Ltd. News
BGNE Breaking Stock News: Dive into BGNE Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
3 days ago
BeiGene opens biologics facility in New Jersey, US
MT Newswires
3 days ago
BeiGene Opens Flagship US Biologics Manufacturing Facility in New Jersey
Business Wire
4 days ago
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
MT Newswires
9 days ago
BeiGene Names Aaron Rosenberg CFO
Business Wire
9 days ago
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
MT Newswires
11 days ago
Nomura Adjusts BeiGene Price Target to $266 From $248.41, Maintains Buy Rating
Simply Wall St.
15 days ago
When Will BeiGene, Ltd. (NASDAQ:BGNE) Become Profitable?
GuruFocus.com
a month ago
Insider Sale: CFO Julia Wang Sells Shares of BeiGene Ltd (BGNE)
Compare BGNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BGNE BeiGene Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.